BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 33301050)

  • 1. KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.
    Estave PM; Spodnick MB; Karkhanis AN
    Handb Exp Pharmacol; 2022; 271():351-377. PubMed ID: 33301050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.
    Karkhanis A; Holleran KM; Jones SR
    Int Rev Neurobiol; 2017; 136():53-88. PubMed ID: 29056156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.
    Ehrich JM; Messinger DI; Knakal CR; Kuhar JR; Schattauer SS; Bruchas MR; Zweifel LS; Kieffer BL; Phillips PE; Chavkin C
    J Neurosci; 2015 Sep; 35(37):12917-31. PubMed ID: 26377476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.
    Anderson RI; Becker HC
    Alcohol Clin Exp Res; 2017 Aug; 41(8):1402-1418. PubMed ID: 28425121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optogenetic stimulation of lateral hypothalamic orexin/dynorphin inputs in the ventral tegmental area potentiates mesolimbic dopamine neurotransmission and promotes reward-seeking behaviours.
    Thomas CS; Mohammadkhani A; Rana M; Qiao M; Baimel C; Borgland SL
    Neuropsychopharmacology; 2022 Feb; 47(3):728-740. PubMed ID: 34663867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake.
    Schindler AG; Messinger DI; Smith JS; Shankar H; Gustin RM; Schattauer SS; Lemos JC; Chavkin NW; Hagan CE; Neumaier JF; Chavkin C
    J Neurosci; 2012 Dec; 32(49):17582-96. PubMed ID: 23223282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addiction as a stress surfeit disorder.
    Koob GF; Buck CL; Cohen A; Edwards S; Park PE; Schlosburg JE; Schmeichel B; Vendruscolo LF; Wade CL; Whitfield TW; George O
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):370-82. PubMed ID: 23747571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis.
    Pirino BE; Spodnick MB; Gargiulo AT; Curtis GR; Barson JR; Karkhanis AN
    Neuropharmacology; 2020 Dec; 181():108341. PubMed ID: 33011200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynorphin and κ-Opioid Receptor Dysregulation in the Dopaminergic Reward System of Human Alcoholics.
    Bazov I; Sarkisyan D; Kononenko O; Watanabe H; Yakovleva T; Hansson AC; Sommer WH; Spanagel R; Bakalkin G
    Mol Neurobiol; 2018 Aug; 55(8):7049-7061. PubMed ID: 29383684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.
    Chartoff EH; Ebner SR; Sparrow A; Potter D; Baker PM; Ragozzino ME; Roitman MF
    Neuropsychopharmacology; 2016 Mar; 41(4):989-1002. PubMed ID: 26239494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.
    Bruchas MR; Land BB; Chavkin C
    Brain Res; 2010 Feb; 1314():44-55. PubMed ID: 19716811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction.
    Chartoff EH; Mavrikaki M
    Front Neurosci; 2015; 9():466. PubMed ID: 26733781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.
    Koob GF
    Psychopharmacology (Berl); 2017 May; 234(9-10):1315-1332. PubMed ID: 28050629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.
    Land BB; Bruchas MR; Lemos JC; Xu M; Melief EJ; Chavkin C
    J Neurosci; 2008 Jan; 28(2):407-14. PubMed ID: 18184783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the kappa opioid receptor system in opioid use.
    Cayir S; Zhornitsky S; Barzegary A; Sotomayor-Carreño E; Sarfo-Ansah W; Funaro MC; Matuskey D; Angarita G
    Neurosci Biobehav Rev; 2024 Jul; 162():105713. PubMed ID: 38733895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk Between Kappa Opioid and Dopamine Systems in Compulsive Behaviors.
    Escobar ADP; Casanova JP; Andrés ME; Fuentealba JA
    Front Pharmacol; 2020; 11():57. PubMed ID: 32132923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. kappa-Opioid receptor signaling and brain reward function.
    Bruijnzeel AW
    Brain Res Rev; 2009 Dec; 62(1):127-46. PubMed ID: 19804796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kappa opioid receptor agonist U50,488 inhibits dopamine more in caudal than rostral nucleus accumbens core.
    Karkhanis AN; West AM; Jones SR
    Basic Clin Pharmacol Toxicol; 2023 Nov; 133(5):526-534. PubMed ID: 37539456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.
    Potter DN; Damez-Werno D; Carlezon WA; Cohen BM; Chartoff EH
    Biol Psychiatry; 2011 Oct; 70(8):744-753. PubMed ID: 21757186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term plasticity of corticostriatal synapses is modulated by pathway-specific co-release of opioids through κ-opioid receptors.
    Hawes SL; Salinas AG; Lovinger DM; Blackwell KT
    J Physiol; 2017 Aug; 595(16):5637-5652. PubMed ID: 28449351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.